메뉴바로가기 본문바로가기

pipeline

인류의 안전과 건강 증진에 기여하는 기업, (주)인테라입니다.

InThera’s E.coli - based VLP manufacturing technology can be applied to abroad range of novel vaccine development. Our diverse pipeline includes unmet-need human vaccines and improved veterinary vaccines.

01Strength & Competitiveness of InThera’s next-generation VLP Vaccine
Target Vaccine Market Strategy Market Size
(at peak sales)
Human unmet vaccine Norovirus Novel unmet vaccine 600 Million USD
Hand, Foot and Mouth Disease(HFMD) Virus Improved efficacy and safety profile over inactivated vaccine ~ 889 Million USD